-
Mashup Score: 69
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 65
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 65
Use of surrogates as primary endpoints is commonplace in hematology/oncology clinical trials. As opposed to prognostic markers, surrogates are endpoints th
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 158
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5More Robust Data Should Be Required Before Drugs Fully Approved - 19 day(s) ago
Abstract: Many cancer drugs are converted from accelerated to regular approval by the FDA despite a lack of proof that patients will reap clinically meaningful benefits from their use. Researchers suggest the FDA withhold regular approval of a drug until its manufacturer implements a trial design that can robustly demonstrate its benefit to patients.
Source: aacrjournals.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 154
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 150
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 149
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 149
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 146
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk fo…
Source: www.nejm.orgCategories: General Medicine News, Partners & KOLsTweet
What clinicians should know about surrogate endpoints Nice work @ComeBommier @MaurerStats Many great examples woven into a thoughtful piece https://t.co/NRGgyxw3QV @BloodJournal